Arcturus Therapeutics Holdings Inc.ARCTNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank87
5Y CAGR-18.4%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-18.4%/yr
Long-term compound
Percentile
P87
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 34.90% |
| Q3 2025 | 0.58% |
| Q2 2025 | -8.63% |
| Q1 2025 | -8.60% |
| Q4 2024 | -6.75% |
| Q3 2024 | 7.79% |
| Q2 2024 | -17.07% |
| Q1 2024 | 18.74% |
| Q4 2023 | -6.50% |
| Q3 2023 | 1.15% |
| Q2 2023 | -3.90% |
| Q1 2023 | 16.04% |
| Q4 2022 | -5.03% |
| Q3 2022 | 13.60% |
| Q2 2022 | 2.45% |
| Q1 2022 | -15.55% |
| Q4 2021 | 17.00% |
| Q3 2021 | 8.15% |
| Q2 2021 | 3.07% |
| Q1 2021 | -10.89% |
| Q4 2020 | 96.23% |
| Q3 2020 | 26.06% |
| Q2 2020 | 5.46% |
| Q1 2020 | 0.00% |
| Q4 2019 | 7.99% |
| Q3 2019 | 12.30% |
| Q2 2019 | -2.21% |
| Q1 2019 | 2.70% |
| Q4 2018 | -9.69% |
| Q3 2018 | -53.72% |
| Q2 2018 | 61.49% |
| Q1 2018 | 92.02% |
| Q4 2017 | 61.30% |
| Q3 2017 | -21.28% |
| Q2 2017 | 77.20% |
| Q1 2017 | -8.24% |
| Q4 2016 | 6.19% |
| Q3 2016 | -13.62% |
| Q2 2016 | -3.84% |
| Q1 2016 | 10.04% |